Departure of Directors or Certain
Effective as of October 1, 2017, Anavex Life Sciences Corp., a Nevada corporation (the Company), entered into an Amended and Restated Employment Agreement (the Amended Agreement) with Sandra Boenisch, in her continuing capacity as Principal Financial Officer of the Company. The Amended Agreement replaces the prior employment agreement with Ms. Boenisch, dated September 17, 2015 (the Original Agreement), which expired as of October 1, 2017.
The Amended Agreement provides for a base salary of $120,000 CAD and clarifies certain of Ms. Boenischs duties to the Company, but is otherwise materially similar to the Original Agreement. The Original Agreement is filed as Exhibit 10.92 to the Companys Annual Report on Form 10-K, filed on December 29, 2015 and is incorporated herein by reference.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ANAVEX LIFE SCIENCES CORP.
/s/ Christopher Missling
Name: Christopher Missling, PhD
Title: Chief Executive Officer
Date: October 6, 2017
Market Data 
Markets 
AI
